Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.

[1]  Jimin Gao,et al.  Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer , 2011, Cancer Immunology, Immunotherapy.

[2]  C. Piccirillo,et al.  IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease , 2010, Journal of Translational Medicine.

[3]  W. Yin,et al.  A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer. , 2010, Vaccine.

[4]  V. Schijns,et al.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. , 2010, Anti-cancer agents in medicinal chemistry.

[5]  Jimin Gao,et al.  A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF , 2009, Journal of cellular and molecular medicine.

[6]  A. Viola,et al.  Tunable Chemokine Production by Antigen Presenting Dendritic Cells in Response to Changes in Regulatory T Cell Frequency in Mouse Reactive Lymph Nodes , 2009, PloS one.

[7]  Gao Ji-min.  Preparation and Characterization of SA-hIL2 Fusion Protein , 2009 .

[8]  Linjiang Zhu,et al.  IL-2 Family of Cytokines in T Regulatory Cell Development and Homeostasis , 2008, Journal of Clinical Immunology.

[9]  T. Whiteside,et al.  A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-β1 Mediates Suppression in the Tumor Microenvironment , 2007, Clinical Cancer Research.

[10]  R. M. Simpson,et al.  The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. , 2007, Vaccine.

[11]  Rong-cheng Luo,et al.  GM-CSF-surface-modified B16.F10 melanoma cell vaccine. , 2006, Vaccine.

[12]  J. Hamilton,et al.  Functions of granulocyte-macrophage colony-stimulating factor. , 2005, Critical reviews in immunology.

[13]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[14]  M. Perales,et al.  Granulocyte-Macrophage Colony Stimulating Factor: An Adjuvant for Cancer Vaccines , 2004, Hematology.

[15]  Ethan M. Shevach,et al.  Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function , 2004, The Journal of Immunology.

[16]  B. Nelson.  IL-2, Regulatory T Cells, and Tolerance , 2004, The Journal of Immunology.

[17]  N. James,et al.  The systemic treatment of advanced and metastatic bladder cancer. , 2003, The Lancet. Oncology.

[18]  D. Metzinger,et al.  A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. , 2003, Cancer research.

[19]  E. Wherry,et al.  Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.

[20]  W. Alvord,et al.  Immune Effects of Escalating Doses of Granulocyte-Macrophage Colony-Stimulating Factor Added to a Fixed, Low-Dose, Inpatient Interleukin-2 Regimen: A Randomized Phase I Trial in Patients With Metastatic Melanoma and Renal Cell Carcinoma , 2003, Journal of immunotherapy.

[21]  R. Vile,et al.  Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. , 2001, Critical reviews in oncology/hematology.

[22]  P. Hertzog,et al.  Differential Production of IL-12, IFN-α, and IFN-γ by Mouse Dendritic Cell Subsets1 , 2001, The Journal of Immunology.

[23]  B. Bodey,et al.  Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. , 2000, Anticancer research.

[24]  R. Dillman.  What to do with IL-2? , 1999, Cancer biotherapy & radiopharmaceuticals.

[25]  G. Schuler,et al.  Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. , 1999, Journal of immunological methods.

[26]  A. Szilvasi,et al.  Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro , 1996, Cancer Immunology, Immunotherapy.

[27]  H. Lyerly,et al.  Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  G. Schuler,et al.  Understanding the dendritic cell lineage through a study of cytokine receptors , 1994, The Journal of experimental medicine.